As of close of business last night, G1 Therapeutics Inc’s stock clocked out at $3.32, down -4.60% from its previous closing price of $3.48. In other words, the price has decreased by -$0.1600 from its previous closing price. On the day, 821994 shares were traded.
Ratios:
To gain a deeper understanding of GTHX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 1.62 whereas as Long-Term Debt/Eq ratio is at 1.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 12 ’24 when Malik Rajesh sold 28,600 shares for $4.62 per share. The transaction valued at 132,143 led to the insider holds 169,938 shares of the business.
MURDOCK TERRY L sold 721 shares of GTHX for $2,121 on Jan 04 ’24. The Chief Operating Officer now owns 103,638 shares after completing the transaction at $2.94 per share. On Jan 04 ’24, another insider, Avagliano Mark, who serves as the Chief Business Officer of the company, sold 721 shares for $2.94 each. As a result, the insider received 2,121 and left with 117,834 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GTHX now has a Market Capitalization of 173.04M and an Enterprise Value of 146.78M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.10 while its Price-to-Book (P/B) ratio in mrq is 4.87. Its current Enterprise Value per Revenue stands at 1.78 whereas that against EBITDA is -4.28.
Stock Price History:
Over the past 52 weeks, GTHX has reached a high of $5.00, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 3.4211, while the 200-Day Moving Average is calculated to be 2.3752.
Shares Statistics:
It appears that GTHX traded 1.69M shares on average per day over the past three months and 1.36M shares per day over the past ten days. A total of 51.93M shares are outstanding, with a floating share count of 42.49M. Insiders hold about 18.61% of the company’s shares, while institutions hold 24.15% stake in the company. Shares short for GTHX as of Feb 29, 2024 were 2.91M with a Short Ratio of 1.72, compared to 2.61M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.58% and a Short% of Float of 5.63%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.22, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.19 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.63 and -$0.79 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.45, with 4 analysts recommending between -$0.3 and -$0.65.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $15.26M. It ranges from a high estimate of $16M to a low estimate of $14.5M. As of the current estimate, G1 Therapeutics Inc’s year-ago sales were $12.95M, an estimated increase of 17.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $16.41M, a decrease of -61.30% less than the figure of $17.90% in the same quarter last year. There is a high estimate of $18.05M for the next quarter, whereas the lowest estimate is $15.29M.
A total of 6 analysts have provided revenue estimates for GTHX’s current fiscal year. The highest revenue estimate was $75.04M, while the lowest revenue estimate was $62.13M, resulting in an average revenue estimate of $69.87M. In the same quarter a year ago, actual revenue was $82.51M, down -15.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $103.47M in the next fiscal year. The high estimate is $139.32M and the low estimate is $67.9M. The average revenue growth estimate for next year is up 48.10% from the average revenue estimate for this year.
